ClinicalTrials.gg
RecruitingNCT07493148Updated Mar 25, 2026

Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL

A Phase 2 interventional study of Chidamide and Rituximab in Diffuse Large B-Cell Lymphoma (DLBCL), sponsored by Ou Bai, MD/PHD. Recruiting at 1 site in China. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Ou Bai, MD/PHD · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing tucidinostat in Lymphoma, Large B-Cell, Diffuse — 11 open to participants now, 11 under way, 2 of them phase 3. tucidinostat · Lymphoma, Large B-Cell, Diffuse.

Planned enrollment
14th of 20
50 · median 61
Started
2026
with 5 others
Phase 2
16 of 20
8 open now
Primary completion
2029-12
later than 10 of 10 live
Registered
16th of 20
by date
Lead sponsor
3 of 20
Ou Bai, MD/PHD

Among the 20 studies testing tucidinostat in Lymphoma, Large B-Cell, Diffuse, this one is the 14th largest by planned enrollment, is one of 6 that started in 2026, is one of 16 in phase 2, reaches primary completion later than 10 of the 10 other live ones, and was the 16th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

11 of the 20 studies testing tucidinostat in Lymphoma, Large B-Cell, Diffuse are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

About tucidinostat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing tucidinostat in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

Efficacy and safety of chidamide in combination with the R-mini CHOP regimen, followed by chidamide plus CD20 monoclonal antibody as maintenance therapy, in elderly patients with newly diagnosed MYC/BCL2 double-expressor DLBCL.

Read the detailed description

The primary study objective is to evaluate the 2-year progression-free survival (PFS) rate of chidamide in combination with the R-miniCHOP regimen. Secondary objectives include the objective response rate (ORR), duration of response (DOR), complete response (CR) rate, the percentage of patients converting from PR/SD to CR/PR, overall survival (OS), and safety parameters. The exploratory objective is to investigate the correlation between biomarkers (e.g., tumor genomics, proteomics) and ctDNA with treatment efficacy.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma (DLBCL)

Keywords

  • newly diagnosed MYC/BCL2 double-expressor DLBCL
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 70 years;
  2. No prior treatment for DLBCL;
  3. Histopathologically confirmed diagnosis (all of the following conditions must be met simultaneously): ① Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), and CD20-positive; ② "MYC/BCL2 double-expressor": Immunohistochemistry (IHC) per WHO criteria: MYC ≥ 40%, and BCL2 ≥ 50%; ③ Non-"double-hit" or "triple-hit" lymphoma;
  4. At least one 18F-fluorodeoxyglucose (18FDG)-avid lesion on positron emission tomography-computed tomography (PET-CT) according to the 2014 Lugano classification for Hodgkin and non-Hodgkin lymphoma;
  5. International Prognostic Index (IPI) score > 1;
  6. (ECOG) performance status of 0, 1, or 2;
  7. At screening, laboratory tests must meet the following criteria, unless judged by the investigator to be due to lymphoma (no corrective or supportive treatment for the indicators below within 2 weeks prior to assessment): ① Hematology: (Hb) ≥ 90 g/L, (ANC) ≥ 1.5 × 10⁹/L, count (PLT) ≥ 90 × 10⁹/L; ② Biochemistry: Serum creatinine (Cr) ≤ 1.5 × (ULN); Total (TBIL) ≤ 1.5 × ULN; (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN in cases of liver );
  8. ≥ 6 months;
  9. Understand and voluntarily sign a written form.

Exclusion criteria

Exclusion Criteria:

  1. Central nervous system (CNS) involvement;
  2. Transformed lymphoma, i.e., lymphoma transformed from other lymphoma types such as follicular lymphoma, marginal zone B-cell lymphoma, or chronic lymphocytic leukemia/small lymphocytic lymphoma; specific subtypes of DLBCL (e.g., primary CNS DLBCL, etc.);
  3. Uncontrolled cardiovascular or cerebrovascular diseases, coagulation disorders, diseases, or severe infectious diseases;
  4. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies, or known sensitivity or allergic reactions to murine products; to any component of the CHOP regimen or chidamide;
  5. / infection;
  6. If is positive, HBV DNA testing is required; patients with negative DNA may be enrolled. If HBsAg is negative but HBcAb is positive (regardless of HBsAb status), HBV DNA testing is required; patients with negative DNA may be enrolled.
  7. Uncontrolled cardiovascular or cerebrovascular diseases, coagulation disorders, autoimmune diseases, or severe infectious diseases;
  8. Inability to comply with the study protocol due to psychiatric or other unknown reasons;
  9. For female patients of or male patients with partners of childbearing potential, unwillingness or inability to use effective throughout the study treatment period and for 12 weeks after the last dose of chidamide or 12 months after the last dose of rituximab, whichever is longer; pregnant or breastfeeding women;
  10. Other conditions deemed unsuitable for participation in this trial.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Chidamide group

    Chidamide Specification: 5mg / tablet. Induction phase: Chidamide, oral, 20 mg (4 tablets) each time, twice a week, D1-14. 21 days/cycle. R-mini CHOP, Q3W. Maintenance phase: Chidamide, oral, 20 mg (4 tablets) each time, twice a week, D1-14. Rituximab 375 mg/m² IV, once every 12 weeks. 21 days/cycle.

    Drug: Chidamide · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Chidamide + Rituximab maintenance

Interventions

  • DrugTucidinostatStudies of TucidinostatTucidinostat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Chidamide, oral, 20 mg (4 tablets) each time, twice a week, D1-14.

    Also known as: CS055, HBI-8000, Tucidinostat

  • Rituximab, 375 mg/m² IV, Cycle 1-4, Day 1.

    Also known as: MabThera

  • Cyclophosphamide, 400 mg/m² IV, Cycle 1-4, Day 2.

    Also known as: Cytoxan

  • Doxorubicin, 25 mg/m² IV, Cycle 1-4, Day 2.

    Also known as: Hydroxydaunorubicin

  • Vincristine, 1 mg/m² IV, Cycle 1-4, Day 2.

    Also known as: VCR

  • Prednisone, 40 mg/m² orally, Cycle 1-4, Days 1-5.

  • DrugChidamide + Rituximab maintenance

    Drug pages: TucidinostatStudies of TucidinostatTucidinostat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · RituximabStudies of RituximabRituximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Chidamide, oral, 20 mg (4 tablets) each time, twice a week, D1-14. Rituximab, 375 mg/m² IV, once every 12 weeks. 21 days/cycle.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    The time from study enrollment to the first documented disease progression or death from any cause, whichever occurs first.

    Time frame: 24 months

Secondary outcomes

  1. Overall Response Rate (ORR)

    To assess the Overall Response Rate (ORR) referred to Lugano 2014.

    Time frame: 24 months

  2. Duration of Response (DOR)

    The duration from the first documentation of response (achievement of complete response or partial response) to the first unequivocal evidence of relapse or progression.

    Time frame: 24 months

  3. Complete Response Rate (CRR)

    To assess the Complete Response Rate (CRR) referred to Lugano 2014.

    Time frame: 24 months

  4. Percentage of patients converting from PR/SD to CR/PR

    Percentage of patients converting from PR/SD to CR/PR

    Time frame: 24 months

  5. Overall survival(OS)

    Overall survival(OS) is defined as the time from the date of enrollment to the date of death from any cause.

    Time frame: 24 months

  6. Adverse Events

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment, assessed by NCI-CTCAE v5.0. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: 24 months

Other outcomes

  1. Biomarker exploration

    ctDNA testing will be performed at baseline, after 6 cycles of treatment, every 6 months during the maintenance period, and at disease progression or study withdrawal, to evaluate the correlation between ctDNA and treatment efficacy.

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2029, 44 months later.

Of 211 non-industry phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 44 months is below that.

Counting every sponsor, half of 264 studies reached it within 52 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Mar 25, 2026
StartEst.
Apr 30, 2026
Primary completionEst.
Dec 30, 2029
CompletionEst.
Dec 30, 2029
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07493148
Lead sponsor
Ou Bai, MD/PHD
Responsible party
Ou Bai, MD/PHD (Director, The First Hospital of Jilin University) — Sponsor-investigator
First posted
Mar 25, 2026
Start date
Apr 30, 2026 (estimated)
Primary completion
Dec 30, 2029 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Mar 25, 2026

Study contacts

Ou Bai, PHD
Contact
oubai16@163.com
13039046656
Ou Bai, PHD
principal investigator · The First Bethune Hospital of Jilin University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tucidinostat · Rituximab

Start the discussion